Eli Lilly and Company (NYSE:LLY) Stock Holdings Lifted by Xponance Inc.

Xponance Inc. boosted its position in Eli Lilly and Company (NYSE:LLY) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 191,009 shares of the company’s stock after purchasing an additional 1,718 shares during the period. Eli Lilly and Company comprises 1.3% of Xponance Inc.’s portfolio, making the stock its 10th biggest holding. Xponance Inc.’s holdings in Eli Lilly and Company were worth $111,343,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in LLY. AIA Group Ltd raised its stake in Eli Lilly and Company by 2.7% during the 4th quarter. AIA Group Ltd now owns 17,719 shares of the company’s stock valued at $10,329,000 after purchasing an additional 467 shares during the period. Cambridge Trust Co. raised its stake in Eli Lilly and Company by 0.7% during the 4th quarter. Cambridge Trust Co. now owns 10,930 shares of the company’s stock valued at $6,371,000 after purchasing an additional 78 shares during the period. Oliver Lagore Vanvalin Investment Group increased its stake in Eli Lilly and Company by 27.7% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 387 shares of the company’s stock worth $226,000 after acquiring an additional 84 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV increased its stake in Eli Lilly and Company by 7.6% in the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 8,894 shares of the company’s stock worth $5,165,000 after acquiring an additional 630 shares during the last quarter. Finally, Tufton Capital Management increased its stake in Eli Lilly and Company by 430.9% in the 4th quarter. Tufton Capital Management now owns 2,336 shares of the company’s stock worth $1,362,000 after acquiring an additional 1,896 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

LLY stock traded down $4.82 during mid-day trading on Thursday, reaching $745.95. 1,701,231 shares of the company’s stock were exchanged, compared to its average volume of 3,060,988. The company has a market cap of $708.77 billion, a price-to-earnings ratio of 129.32, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The stock’s 50 day moving average is $764.03 and its 200 day moving average is $657.67. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 12-month low of $367.35 and a 12-month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.09 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on LLY shares. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Truist Financial restated a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 22nd. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Citigroup upped their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Finally, BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $728.05.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.